 Eidos Therapeutics NASDAQ:EIDX was upgraded by research analysts at ValuEngine from a sell rating to a hold rating in a research note issued on Tuesday, ValuEngine reports. Several other research firms have also recently weighed in on EIDX. Piper Sandler boosted their price target on shares of Eidos Therapeutics from 75.00 to 80.00 and gave ... 